Related Experiment Video
Updated: Jul 5, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Social Determinants of Outcomes Disparity among Pediatric Patients with Solid Tumor
Elizabeth D Cochran1, Jillian C Jacobson1, Mithin Nehrubabu2
1From the Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX (Cochran, Jacobson, Qiao, McCreery, Chung).
Insights
Socioeconomic factors like area deprivation index (ADI) significantly impact pediatric solid tumor outcomes. Higher ADI scores and minority racial status increase mortality risk, highlighting disparities in care.
Area of Science:
- Pediatric Oncology
- Health Services Research
- Social Epidemiology
Background:
- Socioeconomic factors significantly influence healthcare outcomes.
- Area Deprivation Index (ADI) quantifies socioeconomic determinants of health.
- Understanding these impacts is crucial for improving pediatric cancer care.
Purpose of the Study:
- To assess the impact of socioeconomic factors on clinical outcomes in pediatric patients with solid tumors.
- To identify specific social determinants of health associated with disparities in outcomes.
- To inform targeted interventions for at-risk populations.
Main Methods:
- Retrospective analysis of 3,863 pediatric solid tumor patients from the Texas Cancer Registry (1995-2019).
- Utilized Area Deprivation Index (ADI) to measure socioeconomic status.
- Employed logistic regression, linear regression, Cox proportional hazards regression, and Kaplan-Meier survival analysis.
Main Results:
- Increased risk of death was associated with Black race, rare minority races, residence in border counties, and higher ADI scores.
- Each one-point increase in ADI score correlated with a 4% rise in the 5-year risk of death.
- Demographic breakdown: 53.5% male, average age 4.5 years; 47% White, 13.3% Black, 36.2% Hispanic, 1.7% Asian.
Conclusions:
- Social determinants of health are linked to unequal outcomes in pediatric solid tumor patients.
- Racial minorities and individuals in disadvantaged or border regions face higher mortality risks.
- Findings can guide resource allocation and outreach strategies for vulnerable communities.
Background:
Socioeconomic factors have a significant impact on healthcare outcomes. Metrics such as area deprivation index (ADI) are used to quantify the anticipated influence of these factors. Here, we sought to assess the impact of socioeconomic factors on clinical outcomes among pediatric patients with solid tumor in our region.
Study Design:
We identified 3,863 pediatric patients who were diagnosed with a malignant solid tumor in the Texas Cancer Registry between 1995 and 2019. ADI was used to quantify socioeconomic determinants of health. These outcome variables were determined: stage of disease at diagnosis, time between diagnosis and treatment initiation, and overall mortality. Statistical analysis was performed using logistic regression, linear regression, Cox proportional hazards regression, and Kaplan-Meier survival curves.
Results:
A total of 53.5% of patients were male and the average age at diagnosis was 4.5 years. Forty-seven percent of patients were White, 13.3% were Black, 36.2% were Hispanic, 1.7% were Asian, and other rare minority groups made up 1.8%. On multivariable analysis, increased risk of death was associated with Black race, rare minority race, residence in a border county, and increasing ADI score, with the risk of death at 5 years rising 4% with each increasing ADI point.
Conclusions:
Social determinants of health are associated with disparate outcomes among pediatric patients with solid tumor. Our results suggest that patients who are part of racial minority groups and those who reside in socioeconomically disadvantaged neighborhoods or regions near the Texas-Mexico border are at an increased risk of death. This information may be useful in strategizing outreach and expanding resources to improve outcomes in at-risk communities.
Related Concept Videos
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

